Nilesh Patel, MD
Pulmonary Disease · Salisbury, NCNPI 1053397562
Payments from drug & device makers
Across 335 payments — averaging $339.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$75K
- Astrazeneca UK Limited$33K
- Olympus Corporation Of The Americas$2K
- GSK$743
- Regeneron Healthcare Solutions, Inc.$494
- Amgen$316
- plus $3K from 31 others
What the payments were for
- Consulting fees$190%
- Travel & lodging$1,65424%
- Food & beverage$5,18775%
- Education$831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $74,525 |
| Astrazeneca UK Limited | 3 | $32,999 |
| Olympus Corporation Of The Americas | 11 | $1,726 |
| GSK | 53 | $743 |
| Regeneron Healthcare Solutions, Inc. | 22 | $494 |
| Amgen | 18 | $316 |
| Sanofi | 12 | $272 |
| Grifols USA, LLC | 15 | $263 |
| Boehringer Ingelheim | 12 | $257 |
| United Therapeutics Corporation | 27 | $226 |
| Verona Pharma, Inc. | 13 | $225 |
| Mylan Specialty L.p. | 12 | $181 |
| Philips North America LLC | 8 | $167 |
| Baxter Healthcare | 9 | $163 |
| Insmed, Inc. | 7 | $129 |
| Sunovion Pharmaceuticals Inc. | 17 | $126 |
| Pfizer | 6 | $116 |
| Merck | 6 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $103 |
| Genentech USA, Inc. | 6 | $82 |
| Actelion Pharmaceuticals US, Inc. | 5 | $81 |
| Novo Nordisk | 4 | $77 |
| Electromed, Inc. | 4 | $52 |
| Shire North American Group Inc | 3 | $48 |
| Mallinckrodt Hospital Products Inc. | 3 | $48 |
| Viatris Specialty LLC | 2 | $45 |
| Inspire Medical Systems, Inc. | 1 | $42 |
| ANI Pharmaceuticals, Inc. | 2 | $39 |
| Circassia Inc. | 2 | $31 |
| La Jolla Pharmaceutical Company | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| ADMA Biomanufacturing LLC | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $19 |
| Smith+Nephew | 1 | $19 |
| Masimo Corporation | 1 | $15 |
| Lilly USA, LLC | 1 | $11 |
| Abiomed | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$113,833 in reported general payments places this provider in the 85th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 15 | $209,334 |
| NucalaMepolizumab | 21 | $155,108 |
| OpsumitMacitentan | 11 | $140,561 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 163 | $131,942 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 98 | $76,880 |
| Breo ElliptaFluticasone/Vilanterol | 80 | $41,415 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $34,137 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 57 | $32,296 |
| Spiriva RespimatTiotropium Bromide | 13 | $15,067 |
| EliquisApixaban | 14 | $10,267 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $9,788 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $7,327 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $7,184 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 188 | $4,578 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $3,178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $743 | $369,786339 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $257 | $264,024100 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $81 | $140,56111 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $74,525 | $86,668136 claims |
| PfizerEliquis | $116 | $10,26714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Salisbury
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Murali RamaswamyGreensboro$2M
- Mikell JarrattGastonia$1.7M
- Lake MorrisonDurham$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.